Fycompa is a medicine used to manage partial-onset seizures (also known as focal seizures) in children and adults. Fycompa is a medicine that contains the drug perampanel, which is used to treat ...

Perampanel is a non-competitive antagonist of the ionotropic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor on post-synaptic neurons. Glutamate is the primary ...

Fycompa (perampanel) is currently indicated for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.

However, Fycompa still faces generic competition starting May 2025. So it remains to be seen if they’ll achieve a “managed and gradual” revenue decline. Similarly, CPRX’s recent Teva ...

Japanese pharmaceutical company, Eisai has announced that it is ‘appalled’ by the ruling of The German Federal Joint Committee (G-BA) that the benefits of the antiepileptic treatment, Fycompa ...